High Glucose-induced O-GlcNAcylated Carbohydrate Response Element-binding Protein (ChREBP) Mediates Mesangial Cell Lipogenesis and Fibrosis

THE POSSIBLE ROLE IN THE DEVELOPMENT OF DIABETIC NEPHROPATHY*

Min-Jung Park‡, Dong-Il Kim‡, Seul-Ki Lim‡, Joo-Hee Choi‡, Ho-Jae Han§, Kyung-Chul Yoon‡, and Soo-Hyun Park¶

From the ‡Department of Veterinary Physiology, College of Veterinary Medicine, Chonnam National University, Gwangju 500-757, Korea, the §Department of Veterinary Physiology, College of Veterinary Medicine, Seoul National University, Seoul 151-741, Korea, and the ¶Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju 501-757, Korea

Background: Abnormal lipid synthesis and fibrosis can lead to diabetic nephropathy.

Results: High glucose-induced O-GlcNAcylated ChREBP increases the expression of lipogenic and fibrotic proteins and induces lipid accumulation and fibrosis.

Conclusion: O-GlcNAcylated ChREBP mediates lipogenesis and fibrosis in mesangial cells.

Significance: This is the first report that O-glycosylated ChREBP plays a pathophysiological role in lipogenesis and fibrosis in mesangial cells.

Carbohydrate response element-binding protein (ChREBP) is a transcription factor responsible for carbohydrate metabolism in the liver. However, the role of ChREBP in diabetic nephropathy has not been elucidated. Thus, we investigated the role of ChREBP in mesangial cells in diabetic nephropathy. Treatment with 25 mM glucose (high glucose; HG) increased cellular O-GlcNAc and O-GlcNAcylated ChREBP in mesangial cells compared with normal 5.5 mM glucose. O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino N-phenylcarbamate (PUGNAc), a drug that increases O-GlcNAc, augmented the expression of ChREBP targets, whereas DON, a drug that decreases O-GlcNAc and O-GlcNAcase overexpression, mitigated the increase with HG. O-GlcNAc augmented the protein stability, transcriptional activity, and nuclear translocation of ChREBP. HG treatment also stimulated lipid accumulation and the contents of triglyceride and cholesterol in mesangial cells. In addition, HG triggered expression of hypoxia-inducible factor 1-α, vascular endothelial growth factor, and extracellular matrix components related to nephrosclerosis. The ChREBP mutant, W130A, did not exhibit HG-induced lipid accumulation and fibrotic proteins, suggesting that the Trp-130 residue in the MCR3 domain is important in the development of glomerulosclerosis. O-GlcNAcylated ChREBP was elevated in mesangium cells of streptozotocin-induced diabetic rats. In conclusion, HG increased the O-GlcNAcylated ChREBP level, which resulted in lipid accumulation and up-regulation of fibrotic proteins in mesangial cells. These effects may lead mesangial cells to an ultimately pathological state.

Diabetic nephropathy is a major complication of diabetes mellitus, resulting in high mortality. Hyperglycemia is a primary factor in the development of diabetic nephropathy (1). Abnormal lipid metabolism and renal accumulation of lipids have been proposed to affect the progression of diabetic nephropathy (2–5). Recently, Kiss et al. (6) reported that lipid droplet accumulation in glomeruli is associated with an increase in hyperglycemia-induced renal damage, suggesting a pathophysiological role for lipid accumulation in mesangial cells in diabetic nephropathy. Therefore, understanding lipid metabolism in mesangial cells under a high glucose condition is necessary to comprehend the progress of nephropathy.

Emerging data indicate that GlcNAcylation may play an important role in diabetes. The hexosamine biosynthetic pathway is a branch of the glucose metabolic pathway, consuming approximately 2–5% of total glucose. O-GlcNAc levels in key cellular proteins, including O-GlcNAc transferase (OGT),2 can be modulated by altering the extracellular glucose levels (7–11); thus, O-GlcNAc is hypothesized to be a nutritional sensor in the liver (12). Many reports indicate that O-GlcNAcylation is altered in metabolic diseases, such as diabetes (10, 12–16). Among the proteins associated with glucose metabolism, nuclear receptor liver X receptor is O-GlcNAc-modified in response to glucose (11). In addition, O-GlcNAc modification is essential for the glucose response of carbohydrate response element-binding protein (ChREBP), which controls the expres-

---

2 The abbreviations used are: OGT, O-GlcNAc transferase; ChREBP, carbohydrate response element-binding protein; ChoRE, carbohydrate response element; SREBP, sterol regulatory element-binding protein; Mix, Max-like protein X; ACC, acetyl-CoA carboxylase; FAS, fatty acid synthase; OGA, O-GlcNAcase; L-PK, L-type puruvate kinase; PUGNAc, O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino N-phenylcarbamate; HIF, hypoxia-inducible factor; STZ, streptozotocin; LG, low glucose; HG, high glucose; CHX, cycloheximide; MCR, Mondo conserved region; HRE, hypoxia-responsive element; DON, 6-diazo-5-oxo-l-norleucine.
Functions of O-GlcNAcylated ChREBP in Mesangial Cells

ChREBP is a basic helix-loop-helix leucine zipper transcription factor, a major mediator of glucose action in the liver, and regulates glucose homeostasis in cells with sterol regulatory element-binding protein (SREBP), primarily in the liver (18, 19). As the glucose level rises, ChREBP translocates from the cytosol into the nucleus and forms a heterodimer with Max-like protein X (Mlx) (20) to bind to ChoRE for transcriptional regulation of its target genes, which are particularly associated with glycolysis (L-type puruvate kinase; L-PK (21); lipogenesis (acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS) (22)); and transport, development, and cell motility (23). As mentioned above, indirect evidence indicates that ChREBP is modified by OGT/O-GlcNAcase (OGA) or its inhibitor, DON/PUGNac, and other studies reported this ChREBP modification affects its stability, transcriptional activity, glucose utilization, and lipid synthesis in the liver (17, 24, 25). Although studies of ChREBP function in the kidney are limited, the augmented expression of ChREBP in kidneys of rats with chronic renal failure has been reported (26). Isoe et al. (27) recently reported hypoxia-inducible factor 1-α (HIF-1α) regulation of ChREBP in glomerular mesangial cells. In cultured mesangial cells, high glucose enhances the expression of HIF-1α and its target genes involved in the development of diabetic glomerulosclerosis (27). Therefore, in the study, we examined the role of ChREBP in lipid accumulation and renal fibrosis in mesangial cells. Furthermore, we investigated the role of GlcNAcylation of ChREBP in the progression of diabetic nephropathy, especially in renal fibrosis.

EXPERIMENTAL PROCEDURES

Antibodies and Reagents—All chemicals were obtained from Sigma-Aldrich with the exception of the following: Dulbecco’s modified Eagle’s medium (with low glucose or no glucose) and fetal bovine serum (Invitrogen); PUGNAc (Toronto Research Chemicals, Ontario, Canada); HIF-1 inhibitor (Santa Cruz Biotechnology, Inc., catalogue no. sc-221724); and Protein A/G PLUS-agarose (Santa Cruz Biotechnology). Antibodies against β-actin, lamin B, O-GlcNAc (RL-2), 14–3–3, collagen IV, tubulin, ChREBP (for the proximity ligation assay), and goat IgG were purchased from Sigma-Aldrich. Antibodies against OGT, FAS, VEGF, and HA were purchased from Abcam (Cambridge, MA). Antibodies against ACC, rabbit IgG, and mouse IgG were purchased from Cell Signaling Technology (Beverly, MA). Anti-ChREBP (from Novus Biologicals, except for the proximity ligation assay), anti-fibronectin (BD Biosciences), anti-HIF-1α (Thermo Scientific), and anti-FLAG M2 (Sigma) were obtained from the indicated sources.

Cell Lines and Cell Culture Conditions—Rat mesangial cells and HEK293 cells were purchased from ATCC (CRL-2573TM and CRL-1573TM, respectively). The culture medium for the cells was DMEM, 5.6 mmol/liter glucose, supplemented with 10% fetal bovine serum, streptomycin (100 μg/ml), and penicillin (100 units/ml) at 37 °C in 95% air, 5% CO2. The media were changed every other day. Nearly confluent cells were incubated for 16 h in serum-free medium prior to treatment. Experimental medium was DMEM with low glucose (5.6 mmol/liter) with or without additional an 20 mmol/liter d-glucose or DMEM without glucose (Invitrogen, catalogue no. 11966-025) and lasted 24 h.

Construction of ChREBP Plasmids and Luciferase Assay—Each FLAG-tagged ChREBP wild type and W130A mutant in CMV54 vector, HA-tagged Max-like protein X (Mlx) γ, and 2× ACC ChoRE/PIK (−40) luciferase plasmid (28) were generously provided by Dr. Howard C. Towle (University of Minnesota, Minneapolis, MN) (20). The mesangial cells were transiently transfected with ChREBP wild type or W130A or empty vector plasmids in addition to Mlx, β-galactosidase, and luciferase plasmids. After 24 h, the culture medium was replaced with medium containing the indicated concentrations of glucose and incubated for an additional 24 h. β-Galactosidase plasmid was used as a control for the normalization of transfection efficiency.

Protein Extraction and Western Blotting—The cell pellet or kidney cortex was lysed in NE-PER nuclear and cytoplasmic extraction reagents (Thermo Scientific) or M-PER mammalian protein extraction reagent (Thermo Scientific) containing protease inhibitor mixture (Sigma) and phosphatase inhibitor mixture I + II (Sigma), and fractional protein was extracted according to the manufacturer’s instructions. The protein level was quantified using the Bradford procedure. 30 μg of whole cell extracts, cytoplasmic extracts, or nuclear extracts were separated by SDS-PAGE and transferred to an enhanced nitrocellulose membrane. The blots were then washed with TBST (10 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.1% Tween 20), blocked with 5% skim milk for 1 h, and incubated overnight at 4 °C with the primary antibody at the dilutions recommended by the supplier. The membrane was then washed with TBST, and the secondary antibodies conjugated to horseradish peroxidase were incubated for 1 h at room temperature. The bands were visualized using EZ-Western Lumi Pico Western blotting detection reagents (Daellab Service Co., Seoul, Korea) on x-ray film (Eastman Kodak Co. BioMax light film) or a luminescent image analyzer (ImageQuant LAS4000 mini, GE Healthcare).

RNA Preparation, RT-PCR, and Quantitative RT-PCR—Total RNA was extracted from the cells using TRIzol according to the manufacturer’s instructions (Invitrogen). Reverse transcription was carried out with 1 μg of total RNA using an RT Premix reverse transcription system kit (AccuPower, Seoul, Korea) with oligo(dT)18 primers. 2 μl of the RT products was amplified with a PCR Premix kit (AccuPower, Seoul, Korea). The PCR primer sequences are presented in Table 1. β-Actin was used as a control to confirm the quantity of the RNA. The RT-PCR products were separated and visualized on 1.2% agarose gels. 0.5 μl of the RT products was amplified with Power SYBR Green (Applied Biosystems, Warrington, UK). The primers used are indicated in Table 1. The quantitative RT-PCR products were analyzed using a StepOne™ real-time PCR system (Applied Biosystems, Invitrogen). All samples were analyzed in triplicate and expressed as mean ± S.E.

Cloning and DNA Transfection—Ogt and Oga genes (National Institutes of Health mammalian gene collection) were obtained from Invitrogen. Ogt insert DNA was generated by PCR using primers 5’-aagtgcacctatccttcgtggaac-3’ and 5’-aagtgcacctatccttcgtggaac-3’.
Functions of O-GlcNAcylated ChREBP in Mesangial Cells

TABLE 1

| Primer sequences used in this study |
|-----------------------------------|
| **Gene** | **Forward** | **Reverse** |
| ChREBP | 5′-AGCCCAAAACGACAAATGT-3′ | 5′-TTCTGACCAAAAGAGGAG-3′ |
| Acc | 5′-AGCTGGAAGCTGAGTATGAG-3′ | 5′-ACTGCCGACCGGACCTTGTG-3′ |
| Fas | 5′-CAACATGACAAGCCACGAC-3′ | 5′-GTTCTGGATGTCCTTCTATG-3′ |
| L-PK | 5′-AATGACGTCGTTATCTACCC-3′ | 5′-CTGGGTACAGATTTCACG-3′ |
| O-GlcNAcase (MGEA5) | 5′-GCAGAAGCAAGACTCGAGA-3′ | 5′-TGACACCACTGGACAAAAC-3′ |
| O-GlcNAc transferase | 5′-TTTACAAGCAAGCAGGGGAA-3′ | 5′-CTGACATGCTGAGTCCAGG-3′ |
| Hif-1α | 5′-GTTAATGAGTCTCCCTGCACCTTAACG-3′ | 5′-CTGACATGCTGAGTCCAGG-3′ |
| Vegfa | 5′-GTGGCTGTTGCGCTCTAAAGC-3′ | 5′-CTGACATGCTGAGTCCAGG-3′ |
| Fibronectin | 5′-CCGCTGTGTTGTGTTGCACTCT-3′ | 5′-CTGACATGCTGAGTCCAGG-3′ |
| Collagen 1A1 | 5′-GCGAATGAGTACTGACACGG-3′ | 5′-CTGACATGCTGAGTCCAGG-3′ |
| Collagen 3A1 | 5′-GAGCTGGCAAAACTGGAGA-3′ | 5′-CTGACATGCTGAGTCCAGG-3′ |
| Collagen 4A1 | 5′-AACGCCATTGATGAGTGCTC-3′ | 5′-CTGACATGCTGAGTCCAGG-3′ |
| β-Actin | 5′-AGGCCGGAAGGACCAAGAGG-3′ | 5′-CTGACATGCTGAGTCCAGG-3′ |

5′-aagcgcgctatgtcgtcgactgctctc-3′ from pOTB7-hOGT as a template. Ogt insert DNA was generated by PCR using primers 5′-aagcgcgctatgtcgtcgactgctctc-3′ and 5′-aagcgcgctatgtcgtcgactgctctc-3′ from pCMV-SPORT6-hOGA as a template. Each amplified fragment was digested with SalI and NotI and inserted into pCMV-HA, respectively. Mesangial cells were stabilized for 24 h before they were transfected with the DNAs. The culture medium was exchanged, and the constructs were stabilized for 24 h before they were transfected with the DNAs. The constructs were transfected into the mesangial cells using GeneExpresso Max transfection reagent (Excellgen, Rockville, MD), as instructed by the manufacturers.

Immunoprecipitation—Cells were co-transfected with FLAG-tagged ChREBP and HA-tagged Mlx using GeneExpresso Max transfection reagent (Excellgen, Rockville, MD). After 24 h, cells were collected in 50 mM Tris-Cl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40 with protease inhibitors and then lysed by vortexing. Equal amounts of lysate were incubated overnight with 2 μg of primary antibody rotating at 4 °C, followed by incubation with 30 μl of protein A/G PLUS-agarose (Santa Cruz Biotechnology) for 2 h at 4 °C. Immunoprecipitates were extensively washed, resuspended in 2× sample buffer, boiled for 5 min, and analyzed by immunoblotting. Nuclear extracts of kidney cortexes from streptozotocin-induced diabetic rats or normal rats were immunoprecipitated under the same protocol described above.

Immunofluorescence—Mesangial cells were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS), followed by permeabilization with 0.1% (v/v) Triton X-100, and washed three times for 10 min each with PBS. Cells were incubated for 1 h with 5% (v/v) BSA in PBS and incubated overnight with anti-ChREBP primary antibody (1:500) in a solution containing 5% (v/v) BSA in PBS. Cells were incubated with secondary FITC-conjugated anti-rabbit IgG antibody (Sigma-Aldrich) for an additional 1 h. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) during the final incubation step. Cells were imaged using a microscope (Leica DM IRB, Leica Microsystems Inc. (Deerfield, IL)).

Picrosirius Red Staining—Cells cultured on coverglass with or without additional 30 mM glucose were fixed in 4% paraformaldehyde for 10 min and washed with distilled water. Staining was performed using the Picosirius Red stain kit (Polysciences, Warrington, PA) according to the manufacturer’s instructions. Stained cells were mounted and imaged using a microscope (Nikon Te-300, Nikon).

Proximity Ligation Assay—An in situ proximity ligation assay was performed in adult male Sprague-Dawley rats. Diabetes was induced by injection of streptozotocin (STZ; 35 mg/kg, intraperitoneally) dissolved in cold and fresh citrate buffer (0.1 M and pH 4.5). After 2 weeks, all rats were sacrificed, and kidney extraction was performed. Experiments were performed in accordance with National Institutes of Health animal research standards, and protocols were approved by the Chonnam National University Laboratory Animal Research Center. Fixed kidneys in 10% neutral buffered formalin were embedded in paraffin and cut at a 10-μm thickness. Paraffin sections were paraffinized with Histochoice (Amresco) and rehydrated with serial diluted ethanol. Sections were steamed in sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) for antigen retrieval and washed with PBS. Then a proximity ligation assay was performed using Duolink (Olink Biosciences, Uppsala, Sweden) according to the manufacturer’s instructions. Briefly, the sections were incubated with primary antibodies (anti-ChREBP and RL-2), diluted to 1:20 in antibody diluents supplied, over night at 4 °C. The Duolink proximity ligation assay probes were incubated in a preheated humidity chamber for 1 h at 37 °C, and then, ligation and amplification were performed. To reduce tissue autofluorescence, sections were incubated with copper sulfate (5 mM CuSO4 in 50 mM ammonium acetate buffer, pH 5.0) for 20 min (29), followed by mounting with ProLong® Gold antifade reagent with DAPI (Invitrogen). The stained sections were observed using a BX-40 apparatus (Olympus, Tokyo, Japan) with an eXcope X3 digital camera (DIXI Optics, Daejeon, South Korea).

Quantitation of Triglyceride and Cholesterol—The contents of triglyceride and cholesterol were determined using colorimetric kits (BioVision) according to the manufacturer’s instructions. For triglyceride quantification, cells cultured on 10-cm dishes were homogenized in a 1-mL solution containing 5% Nonidet P-40 in water, heated to 100 °C in a water bath for 5

MAY 9, 2014 • VOLUME 289 • NUMBER 19 JOURNAL OF BIOLOGICAL CHEMISTRY 13521
Functions of O-GlcNAcylated ChREBP in Mesangial Cells

![Diagram](Image)

**FIGURE 1. O-GlcNAc modification of ChREBP in mesangial cells under high glucose.** A, mesangial cells were exposed to the 0, 5.5, or 25 mM glucose for 24 h, and the cells were assessed for the O-GlcNAc-modified protein pools by immunoblotting (IB) using RL-2 antibodies specific to O-GlcNAc. B, mesangial cell ChREBP levels, according to the glucose concentration levels, were determined by immunoblotting. C and D, the O-GlcNAc-modified protein pools and ChREBP levels under palmitic acid were determined. The data are normalized by the quantities of β-actin. E, HA-ChREBP-transfected mesangial cells were treated with or without 25 mM glucose (HG) for 24 h. Cell lysates were immunoprecipitated (IP) with ChREBP antibodies and probed with RL-2 antibodies.

min, and then cooled down to room temperature two times. Samples were centrifuged, and the supernatants were diluted 10-fold with water. For cholesterol quantification, cells were extracted with chloroform/isopropyl alcohol/Nonidet P-40 in a microhomogenizer. Samples were centrifuged at 15,000 × g for 10 min, and supernatants were dried under vacuum for 30 min to remove organic solvent. Dried lipids were dissolved with cholesterol assay buffer. Absorbance was measured at 570 nm.

**Statistical Analysis**—The results were expressed as the mean ± S.E. Values are the mean ± S.E. of three or four independent experiments. All of the experiments were analyzed by analysis of variance. In some experiments, such as RT-PCR and Western immunoblotting using inhibitors, a comparison of the treatment means was made with the control using the Bonferroni-Dunn test. A p value of <0.05 was considered significant.

**RESULTS**

**O-GlcNAc Modification of ChREBP in Mesangial Cells under the High Glucose Condition**—We first examined whether O-GlcNAc in mesangial cells was altered in diabetes. We treated mesangial cells with 0, 5.5 (low glucose; LG), or 25 mM glucose (high glucose; HG) for 24 h and monitored the increase of O-GlcNAc modification under the HG condition, which mimics a diabetic glucose concentration (Fig. 1A). Among proteins related to glucose metabolism, ChREBP, which acts as a glucose sensor, is regulated by O-linked GlcNAc modification (17). To determine whether ChREBP is regulated in mesangial cells under the HG condition, we evaluated ChREBP levels. The ChREBP level was increased under the HG condition (Fig. 1B), whereas palmitic acid did not increase the protein level, although palmitic acid moderately increased the O-GlcNAc pool in a concentration-dependent manner in mesangial cells (Fig. 1, C and D). Furthermore, ChREBP O-GlcNAcylation was increased under the HG condition compared with the LG condition based on immunoprecipitation with an anti-ChREBP antibody followed by immunoblotting with an anti-RL-2 antibody (Fig. 1E). This relationship between ChREBP and the HG condition in mesangial cells warranted further investigation as to whether ChREBP is regulated and plays a role in mesangial cells exposed to HG.

**Effects of OGT and OGA Overexpression under the High Glucose Condition**—To assess the effect of ChREBP O-GlcNAcylation under the HG condition in mesangial cells, the OGT or Mgea5 (which codes for OGA) gene was transfected into mesangial cells. The HG-induced increase in the ChREBP mRNA level was unaffected by overexpression of either OGA or OGT, whereas HG induction of mRNAs of ChREBP target genes (Acc, Fas, and L-pk) was abolished by overexpression of OGA but not OGT (Fig. 2A). Instead, the HG-induced increase in the ChREBP level was affected by OGA (Fig. 2B). When cells were transfected with OGA or OGT, the expression of the other countergene was also increased modestly, possibly because alterations in OGT or OGA protein levels cause a reciprocal change in the expression of the other (30), which might partially explain this discrepancy. Then, when we examined ChREBP transcription using 2×ACC ChoRE/PK (−40) luciferase plasmid, which harbors the pyruvate kinase basal promoter (−40 to +12) driving luciferase expression (28), luciferase activity was increased under HG under both endogenous and exogenous conditions in a manner dependent on Mlx, the functional heteromeric partner of ChREBP (Fig. 2C). The increased activity under HG was abolished by ectopic expression of OGA and augmented synergistically by OGT overexpression, whereas the promoter activities were completely abolished by dominant negative ChREBP W130A, which is mutated in the Trp-130 residue of the MCR3 domain (31) (Fig. 2D). These results suggest that O-GlcNAcylation of ChREBP in response to HG plays a role in its activity in mesangial cells and that the Trp-130 residue in the MCR3 domain is important for this function, although the Trp-130 residue is an undefined site for direct O-GlcNAcylation.

**O-GlcNAcylation of ChREBP Increases Expression of Its Target Genes**—We used an OGA inhibitor, PUGNAc, and a GFAT inhibitor, DON, to elucidate the effect of ChREBP O-GlcNAcylation on gene expression. The ChREBP mRNA level was increased only upon HG treatment, independently of PUGNAc or DON, according to RT-PCR (Fig. 3A), and additional quantitative real-time PCR experiments confirmed HG-dependent and O-GlcNAc-independent ChREBP transcription. However, transcription of ChREBP target genes, such as Acc, Fas, and Hif-1α, were increased by PUGNAc and/or HG; this effect was prevented by pretreatment with DON (Fig. 3B), similar to previous transfection results (Fig. 2B). The transcription levels of these genes were significantly increased under the HG condition and to a greater extent compared with treatment with PUGNAc only. The responses to PUGNAc under the HG condition differed among the target genes; the Fas mRNA level
was increased, whereas those of the other mRNAs were decreased modestly compared with under the HG condition only, suggesting another regulatory mechanism in addition to O-GlcNAc in mesangial cells under the HG condition. Additionally, the levels of ChREBP and its target proteins, ACC, FAS, and HIF-1α, were increased by PUGNAc and/or HG. Moreover, vascular endothelial growth factor (VEGF), a target of HIF-1α, was induced in a pattern similar to ChREBP (Fig. 3C). However, levels of LXRα and SREBP-1c, regulators of both glucose and lipid metabolism mainly in the liver, were not altered significantly either by HG or inhibitors, and moreover, TXNIP, a target protein containing the ChoRE domain within its promoter region, was up-regulated under the HG condition but independently of use of the inhibitors. Additionally, we treated cells with HG with or without DON pretreatment after transfection of FLAG-wild type ChREBP, the FLAG-CREBP W130A mutant, or an empty vector with HA-Mlx in human embryonic kidney 293 (HEK293) cells to confirm the relevance of ChREBP and O-GlcNAc. As shown in Fig. 3D, ectopic expression of ChREBP increased ACC, FAS, HIF-1α, and VEGF levels; indeed, further synergistic increases were noted under the HG condition; these were blocked by pretreatment with DON. Furthermore, ectopic expression of ChREBP W130A mutant prevented the above described effects. These results indicate that both the level of the ChREBP protein and the transcription of the encoding gene are enhanced by HG and/or the HG-induced increase in O-GlcNAc in mesangial cells.

O-GlcNAcylation of ChREBP Increased Its Stability and Nuclear Localization—To further investigate the roles of O-GlcNAcylation in ChREBP stability in mesangial cells under the HG condition, we treated cells with cycloheximide (CHX), a translation inhibitor, which suppresses de novo protein synthesis. As shown in Fig. 4A, CHX treatment induced the degradation of ChREBP, and PUGNAc pretreatment dramatically increased CHX-induced stability of ChREBP under the LG condition, implying that O-GlcNAcylation prevents ChREBP degradation. Moreover, the ChREBP protein level was decreased slightly by CHX treatment under the HG condition, whereas DON treatment significantly abolished the increased protein level (lane 2 versus lanes 6–8). These results suggest that
ChREBP stability is enhanced under the HG condition and that O-GlcNAcylation is important for maintenance of ChREBP stability.

Next, we examined ChREBP localization in mesangial cells following HG treatment. Even under the normal condition, ChREBP is scattered and shuttled between the cytosol and nucleus. Therefore, we investigated whether intracellular ChREBP localization in mesangial cells is altered due to O-GlcNAc under the HG condition. When mesangial cells were treated with HG for various periods of time, the nuclear ChREBP content was increased dramatically, particularly at 24 h (Fig. 4B), and the nucleus/cytosol ChREBP ratio was relatively high in the presence of PUGNAc with or without HG and low in the presence of DON, independently of HG (Fig. 4C). Immunofluorescence analysis of endogenous ChREBP showed that the overall ChREBP protein content was increased, and the protein was more concentrated in the nucleus of mesangial cells treated with HG or PUGNAc (Fig. 4D). These results suggest that O-GlcNAcylation affects the function of ChREBP by enhancing its stability and facilitating its shuttling to the nucleus.

Relation between O-GlcNAc and ChREBP Partners—Additionally, we performed co-transfection with FLAG-ChREBP and HA-Mlx in HEK293 cells followed by immunoprecipitation with an anti-FLAG antibody to investigate whether the interaction between ChREBP and Mlx is altered. The interaction between ChREBP and Mlx was augmented by PUGNAc or HG treatment compared with the control and DON treatment (Fig. 5A). These results suggest that HG-induced O-GlcNAcylation of ChREBP increased its transcriptional activity by regulating the interaction with Mlx, possibly due to a conformational change in ChREBP.

The 14-3-3 protein is proposed to sequester ChREBP in the cytosol (32), but other researchers have suggested that the Mondo conserved region (MCR) domain of ChREBP plays an essential role in glucose activation independently of its interaction with 14-3-3 (31); thus, the role of 14-3-3 remains controversial. Therefore, we evaluated the 14-3-3 protein level in mesangial cells. The 14-3-3 protein level was not affected by HG treatment or O-GlcNAc state; moreover no change in ChREBP binding with 14-3-3 protein under the HG condition was observed (Fig. 5, B and C). These results suggest that 14-3-3 is not regulated by HG-induced O-GlcNAc modification.

O-GlcNAcylation of ChREBP Induces Lipid Accumulation in Mesangial Cells—A number of clinical studies have shown that increased lipid levels are associated with accelerated progres-
sion of renal disease (4, 5, 33). Because the levels of ChREBP and its lipogenic target genes were augmented by PUGNAc and/or HG, we assayed lipid accumulation using Oil Red O staining to elucidate the pathophysiological function of ChREBP in mesangial cells. As shown in Fig. 6A, both PUGNAc and HG induced lipid accumulation compared with control or the HG condition.
with DON pretreatment, similar to that facilitated by the saturated fatty acid, palmitic acid, which was used as the positive control. Moreover, lipid accumulation in ChREBP wild type-transfected HEK293 cells under the HG condition was prevented by pretreatment with DON; no such effects were observed in cells transfected with the ChREBP W130A mutant (Fig. 6B). To examine the type of lipids accumulated in mesangial cells, triglyceride and cholesterol quantification assays were performed. By PUGNAc or HG, triglyceride and cholesterol concentrations were about 60 and 100% increased, respectively, whereas they were decreased by HG with DON (Fig. 6, C and D), suggesting that increased ChREBP level and stability lead to accumulation of neutral lipid. Together, these results indicate that HG-induced O-GlcNAc could cause lipid accumulation through ChREBP modification, leading to further renal disease.

**Hif-1α Induced by ChREBP Regulates Fibrosis-related Gene Expression in Mesangial Cells under High Glucose**—The Vegf gene contains a hypoxia-responsive element (HRE) in the promoter region, suggesting that HIF-1α regulates VEGF transcription, and excess VEGF is considered relevant to the pathogenesis of diabetic nephropathy (34) and focal glomerular sclerosis (35). Recently, VEGF-induced fibronectin up-regulation was reported in mesangial cells (36). Therefore, we assayed the Vegf and fibronectin mRNA levels in the same context by real-time PCR. The Vegf and fibronectin transcription levels were increased by PUGNAc with or without HG (Fig. 7A), similar to Hif-1α (Fig. 3B). Furthermore, the expression level of non-fibrillary type-IV collagen, fibrillary type-I and -III collagens, and a myofibroblast marker, α-smooth muscle actin, also were increased by both PUGNAc and HG (Fig. 7A). A HIF-1α inhibitor, a cell-permeable amidophenolic compound that inhibits HIF-1 transcription and exerts no apparent effect on the cellular Hif-1α mRNA or HIF-1 level, prevented the HG-induced increases in VEGF, fibronectin, and collagen IV protein levels without affecting the ChREBP, ACC, FAS, or HIF-1α protein level (Fig. 7B). These findings suggest a role for O-GlcNAcylated ChREBP in HIF-1α-mediated fibrosis in mesangial cells under the HG condition. Consistent with those findings, picrosirius red staining showed that the increased fibrosis of mesangial cells induced by both PUGNAc and HG and fibrosis was prevented by HIF-1α inhibition (Fig. 7C). Therefore, in mesangial cells treated with HG, O-GlcNAcylated ChREBP mediates lipogenesis and fibrosis by regulating ACC and FAS and regulating HIF-1α, respectively.

**Elevated O-GlcNAcylated ChREBP in Mesangium Cells of Streptozotocin-induced Diabetic Rats**—To determine whether ChREBP is actually O-GlcNAcylated in vivo, we examined the O-GlcNAcylated ChREBP within the mesangium of STZ-induced diabetic rats exhibiting significant hyperglycemia using an in situ proximity ligation assay with anti-ChREBP and RL-2 antibodies, to make ChREBP exhibit fluorescence when it is O-GlcNAcylated. As shown in Fig. 8A, mesangial cells within the mesangium of STZ-induced diabetic mice showed much more fluorescence, compared with those of control mice. Additionally, O-GlcNAcylated ChREBP from nuclear extracts of kidney cortices of STZ rats was considerably higher than that from normal rats, examined by immunoprecipitation.
These results confirmed the augmented ChREBP glycosylation in vivo diabetic model as well as the in vitro model.

**DISCUSSION**

SREBP has been reported to mediate renal lipotoxicity. Levi’s group (37–41) has reported that maladaptive renal cell lipid metabolism is driven by injury-induced type I and II diabetes, caloric overload, and aging. They showed an increase of SREBP-1 and FAS expression, resulting in increased triglyceride accumulation in the glomerular, tubular, and tubulointerstitial cells of streptozotocin-induced rats (37). In addition, along with SREBP-1c, they demonstrated increased ChREBP activity in type 1 diabetic kidney of OVE26 mice (41). However, there is little evidence that elucidates the interaction between ChREBP and lipid metabolism under a hyperglycemic condition in the kidney.

In this study, we investigated the role of ChREBP O-GlcNAcylation, a consequence of enhanced HBP flux, in in vitro models of diabetic nephropathy using mesangial cells. ChREBP is a major mediator of glucose action in the control of both glycolysis and lipogenesis in the liver (42–44). Thus, we focused on lipogenesis, particularly in mesangial cells, because ChREBP expression was augmented in the kidneys of rats with...
chronic renal failure (26), and renal lipotoxicity has been implicated in kidney abnormalities (2–6). In the present study, HG, but not palmitic acid, increased expression levels of ChREBP and its target genes (ACC and FAS); this effect of HG was abolished by overexpression of OGA or treatment with DON. Moreover, HG did not increase LXRs activation in mesangial cells. These results suggest that ChREBP O-GlcNAcylation mediates lipid accumulation in kidney mesangial cells. Our results are partly in agreement with several previous reports. Recently, Goldberg et al. (45) reported that O-GlcNAcylation in the HG condition is coupled to profibrogenic p38 MAPK signaling in mesangial cells. Degrell et al. (46) showed that N-linked N-acetylgalactosamine is present in the glomeruli of patients with diabetic nephropathy. However, the authors did not state that specific factors, such as ChREBP and O-GlcNAcylation, induced lipid accumulation. Because ChREBP O-GlcNAcylation in the liver has been reported previously (17, 24, 25), we focused on ChREBP O-GlcNAcylation in mesangial cells. In this study, we demonstrated that under the HG condition, O-GlcNAc transactivation of ChREBP mediates lipid accumulation in mesangial cells. Furthermore, we showed significantly elevated ChREBP O-GlcNAcylation in the mesangium of the hyperglycemic in vivo model.

The N-terminal segment of ChREBP contains five highly conserved domains designated MCRs, and the W130A mutation in the MCR3 domain is important for glucose activation of ChREBP (31). The novel finding of this study is that the Trp–130 residue in the MCR3 domain of ChREBP is responsible for HG-induced lipid accumulation and lipogenesis in mesangial cells because ChREBP W130A blocked the HG-induced increase in Oil Red O staining and levels of lipogenic proteins. Based on the abolition of transcriptional activities by the W130A mutant, the Trp–130 residue and other residues within MCR3 could influence the environment in which ChREBP is O-GlcNAcylated by glucose. Characterization of the relationship between Trp–130 and O-GlcNAcylation is important; therefore, we attempted to identify the underlying mechanism. Additionally, the interaction between 14-3-3 and ChREBP with the Trp–130 residue is not altered by either O-GlcNAcylation of ChREBP or the O-GlcNAc status in mesangial cells, as shown in Fig. 5B, suggesting that O-GlcNAcylation is irrelevant in the interaction between ChREBP and 14–3–3.

Renal fibrosis is a major characteristic of diabetic glomerulosclerosis. Evidence suggests that diabetic renal fibrosis is associated with an increase in SREBP-1c and ChREBP levels (41). Although research on the function of ChREBP in the kidney is limited, we hypothesized that ChREBP could play a prominent role in renal fibrosis because studies suggest that ChREBP expression is augmented in kidneys of rats with chronic renal failure (26), and HIF-1 signaling is activated by HG through ChREBP in mesangial cells (27). Among many HIF-1 target genes, excess VEGF is considered relevant to the pathogenesis of diabetic nephropathy (34) and focal glomerular sclerosis (34, 35, 47, 48). Several studies have suggested a pivotal role for VEGF in glomerular hypertrophy and extracellular matrix production (47, 48). However, to date, no direct evidence that ChREBP mediates renal fibrosis in the kidney has been presented. Our current results show that under the HG condition, ChREBP O-GlcNAcylation is also involved in renal fibrosis, in which the Trp–130 residue is important also.

In summary, the present study highlights the role of ChREBP glycosylation in lipogenesis and renal fibrosis in mesangial cells under the HG condition. We presented a model of the signaling mechanism associated with HG-induced lipid accumulation and renal fibrosis in mesangial cells (Fig. 9). HG induced the cellular O-GlcNAc pool and ChREBP O-GlcNAcylation, which enhanced the ChREBP level, transcriptional activity, stability, and nuclear localization, thus triggering its target protein signaling, especially that of lipogenic proteins and fibrosis-inducing proteins, which may render mesangial cells susceptible to hyperglycemia. The Trp–130 residue of ChREBP within the MCR domain is an important site in inducing lipogenesis and fibrosis of diabetic nephropathy. These findings could help to determine the role of glucose metabolism in renal pathological conditions and suggest potential targets to prevent the development of mesangial lipotoxicity and sclerosis.
Acknowledgment—We thank Dr. Howard C. Towle (University of Minnesota) for providing constructs of ChREBP and the luciferase assay.

REFERENCES

1. Sun, Y. M., Su, Y., Li, J., and Wang, L. F. (2013) Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem. Biophys. Res. Commun. 439, 359–361
2. Oda, H., and Keane, W. F. (1997) Lipids in progression of renal disease. Kidney Int. Suppl. 62, S36–S38
3. Klahr, S., and Harris, K. (1989) Role of dietary lipids and renal eicosanoids in the progression of renal disease. Kidney Int. Suppl. 27, S27–S31
4. Weinberg, J. M. (2006) Lipotoxicity. Kidney Int. Suppl. 70, e47231–e47231
5. Kiss, E., Kränzlín, B., Wagenblass, K., Bonrouhi, M., Thiery, J., Groene, E., Grønning-Wang, L. M. (2010) Nuclear receptor liver X receptor is a modulator of mitosis-specific phosphorylations on histone H3. J. Biol. Chem. 285, 12195–12203
6. Decaux, J. F., Antoine, B., and Kahn, A. (1989) Regulation of the expression of the L-type pyruvate kinase gene in adult rat hepatocytes in primary culture. J. Biol. Chem. 264, 11584–11590
7. Towle, H. C., Kaytor, E. N., and Shih, H. M. (1997) Regulation of the expression of lipogenic enzyme genes by carbohydrate. Annu. Rev. Nutr. 17, 405–433
8. Jeong, Y. S., Kim, D., Lee, Y. S., Kim, H. J., Han, J. Y., Im, S. S., Chong, H. K., Ahn, Y. H., Ahn, S. M., and Cha, J. Y. (2011) Integrated expression profiling and genome-wide analysis of ChREBP targets reveals the dual role for O-GlcNAcylation and phosphorylation: roles in signal transduction and transcriptional activity in the liver. PLoS One 6, e22544
9. Guinez, C., Filhoulaud, G., Rayah-Benhamed, F., Marmier, S., Dubuquoy, C., Dentin, R., Moldes, M., Burnol, A. F., Yang, X., Lefebvre, T., Girard, J., and Postic, C. (2011) O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver. Diabetes 60, 1399–1413
10. Cho, K. H., Kim, H. J., Kamanna, V. S., and Vaziri, N. D. (2010) Niacin improves renal lipid metabolism and slows progression in chronic kidney disease. Biochim. Biophys. Acta 1800, 6–15
11. Ito, M., Makino, Y., Mizumoto, K., Sakagami, H., Fujita, Y., Honjo, I., Takiyama, Y., Itoh, H., and Haneda, M. (2010) High glucose activates HIF-1 mediated signal transduction in glomerular mesangial cells through a carbohydrate response element binding protein. Kidney Int. 78, 48–59
12. Hart, G. W., Slawson, C., Ramirez-Corra, G., and Lagerlof, O. (2011) Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem. 80, 825–858
13. Hart, G. W., Slawson, C., Copeland, R. J., and Hart, G. W. (2010) O-GlcNAc signaling: a metabolic link between diabetes and cancer? Trends Biochem. Sci. 35, 547–555
14. Sakiyama, H., Fujiwara, N., Noguchi, T., Eguchi, H., Yoshihara, D., Uyeda, K., and Suzuki, K. (2010) The role of O-linked GlcNAc modification on the glucose response of ChREBP. Biochem. Biophys. Res. Commun. 402, 784–789
15. Ferré, P., and Foufelle, F. (2010) Hepatic steatosis: a role for novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes. Metab. 12, 83–92
16. Hart, G. W., Slawson, C., Ramirez-Corra, G., and Lagerlof, O. (2011) Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem. 80, 825–858
17. Tsatsos, N. G., and Towle, H. C. (2006) Glucose activation of ChREBP in mesangial cells is associated with an increase in hyperglycemia-induced ChREBP localization. This, in turn, triggered its target protein signaling, especially that of lipogenic proteins and fibrosis-inducing proteins, which may render mesangial cells susceptible to hyperglycemia.
tein modification cause severe defects in mitotic progression and cytokinesis. J. Biol. Chem. 280, 32944–32956.

31. Davies, M. N., O’Callaghan, B. L., and Towle, H. C. (2008) Glucose activates ChREBP by increasing its rate of nuclear entry and relieving repression of its transcriptional activity. J. Biol. Chem. 283, 24029–24038.

32. Sakiyama, H., Wynn, R. M., Lee, W. R., Fukasawa, M., Mizuguchi, H., Gardner, K. H., Repa, J. J., and Uyeda, K. (2008) Regulation of nuclear import/export of carbohydrate response element-binding protein (ChREBP): interaction of an α-helix of ChREBP with the 14–3-3 proteins and regulation by phosphorylation. J. Biol. Chem. 283, 24899–24908.

33. Amann, K., and Benz, K. (2013) Structural renal changes in obesity and diabetes. Semin. Nephrol. 33, 23–33.

34. Ziyadeh, F. N., and Wolf, G. (2008) Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr. Diabetes Rev. 4, 39–45.

35. LeHir, M., and Kriz, W. (2007) New insights into structural patterns encountered in glomerulosclerosis. Curr. Opin. Nephrol. Hypertens. 16, 184–191.

36. Wu, T., Zhang, B., Ye, F., and Xiao, Z. (2013) A potential role for caveolin-1 in VEGF-induced fibronectin upregulation in mesangial cells: involvement of VEGFR2 and Src. Am. J. Physiol. Renal Physiol. 304, F820–F830.

37. Sun, L., Halaihel, N., Zhang, W., Rogers, T., and Levi, M. (2002) Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J. Biol. Chem. 277, 18919–18927.

38. Wang, Z., Jiang, T., Li, J., Proctor, G., McManaman, J. L., Lucia, S., Chua, S., and Levi, M. (2005) Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 54, 2328–2335.

39. Jiang, T., Wang, Z., Proctor, G., Moskowitz, S., Liebman, S. E., Rogers, T., Lucia, M. S., Li, J., and Levi, M. (2005) Diet-induced obesity in C57BL/6 mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J. Biol. Chem. 280, 32317–32325.

40. Jiang, T., Liebman, S. E., Lucia, M. S., Phillips, C. L., and Levi, M. (2005) Calorie restriction modulates renal expression of sterol regulatory element binding proteins, lipid accumulation, and age-related renal disease. J. Am. Soc. Nephrol. 16, 2385–2394.

41. Proctor, G., Jiang, T., Iwahashi, M., Wang, Z., Li, J., and Levi, M. (2006) Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 55, 2502–2509.

42. Denechaud, P. D., Dentin, R., Girard, J., and Postic, C. (2008) Role of ChREBP in hepatic steatosis and insulin resistance. FEBS Lett. 582, 68–73.

43. Iizuka, K., and Horikawa, Y. (2008) ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome. Endocr. J. 55, 617–624.

44. Denechaud, P. D., Bossard, P., Lobaccaro, J. M., Millatt, L., Staels, B., Girard, J., and Postic, C. (2008) ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver. J. Clin. Invest. 118, 956–964.

45. Goldberg, H., Whiteside, C., and Fantus, I. G. (2011) O-Linked β-N-acetylglucosamine supports p38 MAPK activation by high glucose in glomerular mesangial cells. Am. J. Physiol. Endocrinol. Metab. 301, E713–E726.

46. Degrell, P., Cseh, J., Moháš, M., Molnár, G. A., Pajor, L., Chatham, J. C., Fülöp, N., and Wittmann, I. (2009) Evidence of O-linked N-acetylglucosamine in diabetic nephropathy. Life Sci. 84, 389–393.

47. Amemiya, T., Sasamura, H., Mifune, K., Kitamura, Y., Hirahashi, J., Hayashi, M., and Saruta, T. (1999) Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells. Kidney Int. 56, 2055–2063.

48. Liu, E., Morimoto, M., Kitajima, S., Koike, T., Yu, Y., Shiiki, H., Nagata, M., Watanabe, T., and Fan, J. (2007) Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J. Am. Soc. Nephrol. 18, 2094–2104.